Alpha-1 Antitrypsin Deficiency Market
Alpha-1 Antitrypsin Deficiency Market Infographics

Alpha-1 Antitrypsin Deficiency

According to the National Organization for Rare Disorders (NORD), alpha-1 antitrypsin deficiency (AATD) is a rare hereditary (autosomal recessive) metabolic disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT), found in the blood. It can cause chronic obstructive pulmonary obstructive disease (COPD); COPD may often have emphysema symptoms. Besides, few adults with

AATD develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.


Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation in the 7MM


  • Total Prevalent Cases
  • Symptom-specific Cases
  • Total Diagnosed Cases
  • Genotype-specific Cases
  • Comorbidity-specific Cases


Alpha-1 Antitrypsin Deficiency Epidemiological Insights Observed in the 7MM (2021)

The total number of incident cases of Alpha-1 Antitrypsin Deficiency observed in the 7MM was observed to be 190K in the year 2021.


Alpha-1 Antitrypsin Deficiency Market Insight

The market size of Alpha-1 Antitrypsin Deficiency in the 7MM was found to be approximately USD 1,200 million in 2021.


Alpha-1 Antitrypsin Deficiency Market Strengths

Due to the rising incidence and prevalence of AATD, companies focus on developing effective treatments for patients with better safety compared to the current standard of care. 


Alpha-1 Antitrypsin Deficiency Market Opportunities

Drugs for treating liver disease in AATD have the advantage of grabbing an untapped market in this indication. The first to enter the market is expected to take a greater market segment.


Alpha-1 Antitrypsin Deficiency Emerging Drugs and Key Companies



  • ARO-AAT (Fazirsiran): Arrow Head Pharmaceuticals
  • Alvelestat (MPH-966): Mereo Biopharma
  • Inhaled AAT: Kamada Ltd